ArticleBMC bioinformatics2025
SequenceCraft: machine learning-based resource for exploratory analysis of RNA-cleaving deoxyribozymes.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in DNAzyme Selection, Molecular Engineering and Biomedical Applications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDeoxyribozymes or DNAzymes represent artificial short DNA sequences bearing many catalytic properties. In particular, DNAzymes able to cleave RNA sequences have a huge potential in gene therapy and sequence-specific analytic detection of disease markers. This activity is provided by catalytic cores able to perform site-specific hydrolysis of the phosphodiester bond of an RNA substrate. However, the vast majority of existing DNAzyme catalytic cores have low efficacy in in vivo experiments, whereas SELEX based on in vitro screening offers long and expensive selection cycle with the average success rate of ~ 30%, moreover not allowing the direct selection of chemically modified DNAzymes, which were previously shown to demonstrate higher activity in vivo. Therefore, there is a huge need in in silico approach for exploratory analysis of RNA-cleaving DNAzyme cores to drastically ease the discovery of novel catalytic cores with superior activities.
resultsIn this work, we develop a machine learning based open-source platform SequenceCraft allowing experimental scientists to perform DNAzyme exploratory analysis via quantitative observed rate constant (k
conclusionsThis work represents a significant advancement in DNAzyme research, providing a tool for more efficient discovery of RNA-cleaving DNAzymes. The SequenceCraft platform offers an in silico alternative to traditional experimental approaches, potentially accelerating the development of DNAzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.